Welcome to our dedicated page for McKesson news (Ticker: MCK), a resource for investors and traders seeking the latest updates and insights on McKesson stock.
McKesson Corporation (MCK) delivers vital healthcare supply chain solutions through pharmaceutical distribution, medical-surgical product management, and technology services. This page provides investors and industry observers with direct access to McKesson's official news updates and market-moving developments.
Track earnings announcements, strategic partnerships, and regulatory filings alongside operational milestones shaping McKesson's role in healthcare logistics. Our curated feed consolidates press releases and verified news to help stakeholders monitor the company's performance in pharmaceutical wholesale and healthcare IT innovation.
Discover updates on McKesson's supply chain optimization initiatives, technology platform enhancements, and collaborations with hospitals, pharmacies, and manufacturers. Bookmark this page for efficient monitoring of developments impacting one of North America's leading healthcare distribution networks.
McKesson (NYSE: MCK) has completed its acquisition of a controlling interest in PRISM Vision Holdings, a leading provider of ophthalmology and retina management services. The transaction values at approximately $850 million for an 80% stake, while PRISM physicians retain the remaining 20% interest.
The strategic acquisition aims to establish McKesson as a leading platform in retinal and ophthalmology services, enhancing its differentiated value proposition, clinical services, and distribution offerings. The company also announced it will release its fourth quarter and full year fiscal 2025 financial results after market close on May 8, 2025, followed by an earnings conference call at 4:30 PM Eastern Time.
McKesson (NYSE: MCK) has announced its financial results for the third quarter of fiscal year 2025. The company has also raised its full-year adjusted EPS guidance. The detailed financial results are available on McKesson's Investor Relations website. The company is hosting a live webcast earnings conference call on February 5th at 4:30 PM ET to discuss the results with investors. The webcast, earnings release, financial tables, and presentation slides will be accessible on McKesson's Investor Relations platform.
McKesson (NYSE: MCK) has announced a definitive agreement to acquire an 80% controlling interest in PRISM Vision Holdings for approximately $850 million. PRISM Vision physicians will retain the remaining 20% interest. PRISM Vision is a premier provider of general ophthalmology and retina management services, operating with more than 180 providers across 91 office locations and seven ambulatory surgery centers.
The acquisition will be consolidated within McKesson's U.S. Pharmaceutical segment and is expected to be $0.20 to $0.30 accretive to McKesson's Adjusted Earnings Per Diluted Share in the first 12 months, growing to $0.65 to $0.75 by the end of the third year. The transaction aims to strengthen McKesson's position in retina and ophthalmology care, expand data and analytics capabilities, and enhance clinical research opportunities.
McKesson (NYSE:MCK) has announced its Board of Directors has declared a quarterly dividend of $0.71 per share of common stock. The dividend will be distributed to shareholders of record as of March 3, 2025, with the payment scheduled for April 1, 2025.
McKesson (NYSE: MCK) has successfully completed the divestiture of its Canada-based Rexall and Well.ca businesses to Birch Hill Equity Partners, a Canadian private equity firm, on December 30, 2024. The transaction, which was initially announced in September 2024, aligns with McKesson's strategic focus on capital deployment and prioritization of investments in expanding its oncology and biopharma growth platforms.
McKesson (NYSE: MCK) will release its third quarter fiscal 2025 financial results after market close on Wednesday, February 5, 2025. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results. Chief Executive Officer Brian Tyler and Chief Financial Officer Britt Vitalone will be participating in the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025. The live webcast for each event will be available on McKesson’s Investor Relations website at http://investor.mckesson.com, along with the company’s earnings release, financial tables and slide presentation.
McKesson has announced its fiscal 2025 second quarter financial results. The detailed results are accessible on McKesson’s Investor Relations website. Additionally, the company has raised its full-year adjusted EPS guidance.
McKesson will host a live webcast of the earnings conference call on Wednesday, November 6th at 4:30 PM ET. The webcast and related materials, including the press release, financial tables, and slide presentation, will be available on McKesson's Investor Relations website. Further information about upcoming investor events is also available on the same site.
McKesson (NYSE:MCK) announced that its Board of Directors has declared a regular quarterly dividend of $0.71 per share of common stock. The dividend will be distributed to shareholders of record as of December 2, 2024, with the payment scheduled for January 2, 2025.
McKesson (NYSE: MCK) has announced the release date for its second quarter fiscal 2025 financial results. The company will unveil its earnings after market close on Wednesday, November 6, 2024. Following the release, McKesson will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time.
Investors can access the live webcast on McKesson's Investor Relations website at http://investor.mckesson.com. The website will also provide access to the company's earnings release, financial tables, and slide presentation. This announcement allows shareholders and interested parties to mark their calendars for McKesson's upcoming financial disclosure and discussion of its quarterly performance.
McKesson (NYSE: MCK) has announced the sale of its Canada-based Rexall and Well.ca businesses to Birch Hill Equity Partners, a Canadian private equity firm. This strategic move aligns with McKesson's enterprise strategy to focus on growing its oncology and biopharma services platforms. The transaction allows McKesson to streamline its business and prioritize investments in key growth areas.
Despite this divestiture, McKesson remains committed to its Canadian distribution and biopharma businesses. The company believes that Rexall and Well.ca will benefit from Birch Hill's resources and capital to expand their services across Canada. McKesson Canada intends to continue as a wholesale distribution supplier to both businesses after the transaction closes.
